hope peace

we need peace

[hope peace @MurkyEvilTiger]

其實核心問題就是這個，台灣人一直自傲於人均GDP超過中國，實際上，台灣的GDP要超過中國6.75倍，才有中國人實際的購買力。尤其是轎車，中國有28萬台幣的智能家用轎車，而台灣最便宜89萬台幣。機車台灣8萬台幣，中國8000台幣。豬前腿肉100g台灣27台幣，中國4台幣。
https://t.co/fKSURx2Oav

[Grok @grok]

**Here's a clear comparison using IMF data (April 2026 WEO):**

**2021 actuals:**
- Nominal GDP (current USD): US ~$23.3T > China ~$18.2T
- GDP PPP: China ~$29.4T > US ~$23.7T (China already larger)

**2026 projections (nominal USD):**
- US ~$31.8T > China ~$20.7T (US still leads by ~54%)

Nominal USD reflects market exchange rates and international purchasing power. PPP adjusts for price differences and better measures domestic economic output/size within borders. Both metrics are standard; which one matters depends on the question (trade/finance vs. production volume). China leads on PPP since ~2014–17; US leads on nominal.

[All day Astronomy @forallcurious]

🚨: China's putting data centers on the ocean floor. The ocean itself becomes the cooling system, reducing the energy and water demands traditional data centers require

[Chan Joe @ChanJoe18]

A bicycle path built right over the sea — in Xiamen. Would you ride it?

[酒本正夫 @SakemotoMasao]

アメリカ人も中国の現実をポストする人が増えて来た。トランプ自身が習近平のファンなのだから、以前の様にCIA広報の偽報道メディアで洗脳するのは難しい。洗脳されているのは馬鹿ウヨと情弱の日本人ぐらい。

[Massimo @Rainmaker1973]

These are an example of what in China is called a 'nail house' (dingzihu).

Buildings like this represent those who, like stubborn nails, defy state-ordered evictions and demolitions by refusing to vacate their properties.

[Koichi Kawakami, 川上浩一 @koichi_kawakami]

日本の侵略戦争によるアジアの犠牲者は2000~3000万人と推計されます。日本の敗戦で、大日本帝国によるアジア各地の占領支配が終わったと言えます。写真は、日本軍占領下で数万人の民間人が犠牲となったシンガポールにある「日本占領時期死難人民記念碑」。

[沐沐 @1QjXFRTVJh1497]

@MgLGfsfs0UaNQeO 我知道日本右翼要怎么回复
1 那是旧中国，不是新中国
2 日本也给了ODA低息贷款
3 绝对是假消息！！
4 日本没有请求，是他们自愿帮忙
5 中国依赖日本！如果断交中国就完蛋了

😑看这群白痴看多了我感觉自己对日本右翼非常熟悉

[とよ @MgLGfsfs0UaNQeO]

親中と反日を結びつける馬鹿がいますが、日本が一番感謝すべき国は中国なので親中は反日には絶対なりません。文���を与えてくれ、戦後賠償金を破棄してくれ、残留孤児を育ててくれ、東北を放射能汚染から巨大ポンプ車の無償提供で救ってくれ、貿易最大国。感謝しかありません。

[GeoPaul626 @Paull626]

🇨🇳 China Isn’t Living in 2025: It’s Already Chilling in 2050

Futuristic drone deliveries, robot restaurants, autonomous everything, glowing smart infrastructure, and cityscapes that look like sci-fi movies; all real, all happening right now in China.

Meanwhile in the US: Still debating basic high-speed rail, fixing potholes, and watching infrastructure crumble while trillions disappear into endless wars and defense contracts.

China knows its priority building for the people, not war!
#China2050 #AmazingChina #ChineseInnovation #FutureIsHere #ChinaTech #Infrastructure #Robotics #HighSpeedRail #DroneDelivery #SmartCities

[孤烟暮蝉 @guyanmuchan001]

这两天必须发的视频

[The world in Frames @world_tourists_]

📍Lujiazui, Pudong, Shanghai, China 🇨🇳

[hope peace @MurkyEvilTiger]

廈門真是非常美麗的城市
https://t.co/i1n4EcA0zB

[Jackson Hinkle 🇺🇸 @jacksonhinkle]

🇨🇳 If Communism doesn't work, then why does China look like this?

[Jackson Hinkle 🇺🇸 @jacksonhinkle]

🇨🇳 If Communism doesn't work, then why does China look like this?

[Herlock @datasuki_intj]

一些日本右翼人士或历史修正主义者，似乎格外热衷于使用一种典型的 “whataboutism”式逻辑谬误，试图为日本侵华战争中的罪行开脱，甚至为其翻案。其基本话术大致如下：

首先，他们会选择性地放大、污名化中国国内的某些历史或现实问题，先制造一个前提：即“中国政府也曾对中国人民造成严重伤害”。

其次，他们再借此混淆概念，将日本军国主义对中国发动侵略战争、实施屠杀、掠夺和殖民压迫的行为，降格为与中国内部政治问题同一性质的事件。

最后，他们��过这种偷换概念，把“侵略者对被侵略者的战争罪行”包装成“各国历史上都存在的问题”，从而稀释日本的责任，淡化受害者的苦难，并为日本军国主义进行辩护。

这种逻辑的本质并不是反思历史，而是逃避历史。它恰恰说明：

第一，这些人并非不了解日本在二战中扮演了怎样的角色；相反，他们非常清楚那段历史的性质，因此才需要不断通过转移话题、混淆概念来削弱其道德负担。

第二，他们所谓的“反思”往往只是战败后的策略性沉默，而不是发自内心的历史清算。一旦条件允许，便试图重新美化军国主义叙事，怀念昔日帝国扩张的所谓“荣光”。

第三，他们从未真正面对日本侵略战争给亚洲各国，尤其是中国人民带来的深重灾难。所谓“翻案”，本质上不是对历史的重新理解，而是对战争罪行的二次伤害。

真正的历史反省，不是用别人的错误来抵消自己的罪行；更不是用“你们也有问题”来掩盖侵略、屠杀与殖民压迫的事实。罪行不能通过比较被洗白，责任也不会因为转移话题而消失。

[大拿 @wqnwyf518]

もしアメリカが原子爆弾を使わずに日本を救わなかったら、日本はもうとっくに滅んでいたはずだ。これはみんな心の中で分かっているよね？

[Mh @Mh9178Mh]

@wqnwyf518 兄弟我真绷不住了

[Shenzhen Channel @sz_mediagroup]

Meet the smallest member of the Xiaomi(小米)YU7 family. 😆🏎️ Xiaomi created a custom mini YU7 GT race car and invited a young fan—who once impressed staff by passionately explaining the Xiaomi SU7(小米SU7)in a showroom—to take his very first lap on a track. Don’t worry, Xiaomi says the vehicle comes with strict speed limits and remote-control safety features. Is this the YU0.7? 🌝
@Xiaomi @TansuYegen @Kanthan2030 @XH_Lee23 @Ma_WuKong

Video from 小米汽车

[Shenzhen Channel @sz_mediagroup]

Wow! Dancing lobsters!🤣#Guangdong

[Rafael Dominguez @somoscode]

@angeloinchina China going out of their way to help people of Taiwan even when they may not appreciate it...

[Angelo Giuliano 🇨🇭🇮🇹 @angeloinchina]

China Keeps Cancer Drug Rights at Home in Massive $10.5 Billion Pfizer Deal – Explained 🇨🇳

A Chinese biotech powerhouse, Innovent Biologics, has been cooking up next-gen cancer treatments — think antibody-drug conjugates (ADCs), basically smart bombs that deliver chemo straight to tumor cells with way fewer side effects, plus other advanced multispecific antibodies.

They just dropped a monster $10.5 billion global partnership with Pfizer.

How the money flows:
• $650 million upfront cash to Innovent.
• Up to $9.85 billion more in milestone payments if the drugs hit development, approval, and sales targets.
• Plus ongoing royalties on everything Pfizer sells outside China.

Who gets what rights?
• Pfizer gets exclusive rights to develop, manufacture, and sell most of these drugs in the US, Europe, and rest of the world.
• On some programs they’ll co-develop and share profits in the US/EU.
• But here’s the China part: Innovent keeps full rights in Greater China (mainland China, Hong Kong, Macau, and Taiwan). They can develop, produce, price, and sell these exact same drugs in their home market completely on their own, no Pfizer approval needed.

This deal covers multiple early-stage oncology assets, mainly differentiated ADCs and next-gen antibody therapies. Innovent handles early development, Pfizer takes the global later stages and commercialization outside China.

Why this matters (classic China biotech playbook):
Chinese companies create innovative drugs in a fast, lower-cost environment. They license the global rights (ex-China) to Big Pharma giants like Pfizer for massive cash and worldwide reach. At the same time, they never surrender control at home.
Result?
• China exports the innovation and banks billions.
• Chinese patients can get faster, potentially much more affordable access.
• Expected reality: Pfizer is likely to jack up prices significantly when these drugs are commercialized in the West (standard Big Pharma pricing in high-margin markets with less government control), while Innovent will keep them much cheaper in China thanks to domestic pricing pressures and volume strategy.
• Domestic firms keep building R&D, manufacturing, and commercial muscle.
• China strengthens its grip on the world’s second-largest pharma market.
Win-win, Chinese style: Out-license globally, dominate locally. Pfizer gets fresh oncology firepower for its international pipeline (at premium Western prices). Innovent gets validation and capital to keep scaling while protecting affordable access back home.

This is exactly how China’s biotech sector is playing the long game — smart IP strategy, home-market protection, and global cash flow all at once.

[姜是姜子牙的姜 @Girl_in_HuaXi]

感谢某小贼供图，就问如果解放军真的对学生实施所谓坦克碾压和机枪扫射，学生们还会救护解放军吗？